Ruchi Garg

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.”.

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more